newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment

  • IGC Pharma announced the launch of PRISM, an application layer designed to translate its MINT-AD Alzheimer's AI platform into real-world healthcare workflows.
  • PRISM enables early Alzheimer's risk stratification, cognitive health tracking, clinical trial optimization, and personalized brain-health programs.
  • The company is evaluating business-to-business, business-to-business-to-consumer, and online commercialization opportunities for the PRISM ecosystem.
  • IGC cites a global economic burden of dementia exceeding $1.3 trillion annually, potentially reaching $2.8 trillion by 2030.
  • MINT-AD identifies & stratifies Alzheimer's risk using diverse global datasets, while PRISM connects these insights to structured monitoring & intervention workflows.
  • Potential deployment targets include physician practices, memory clinics, pharmaceutical companies, clinical trial sponsors, healthcare networks, insurers, & consumer platforms.
  • IGC Pharma also developed the Agentic Harmonization Assistant (AHA), which reportedly reduced data harmonization time by approximately 90% in internal workflows.
  • PRISM complements the company's clinical-stage strategy, specifically the Phase 2 CALMA trial for IGC-AD1, which completed enrollment with topline results expected in Q4 2026.
  • MINT-AD, PRISM, & AHA are investigational AI-enabled platforms not approved as diagnostic products or intended to replace clinical judgment.
  • The press release includes standard forward-looking statements regarding technology development, commercialization, & regulatory considerations.